Eugenol derivatives containing 1,2,3-triazole-chalcone hybrids for shikimate kinase inhibition

Bayu Ardiansah, Ahmad Farhan, Amalia Firdaus, Titin Ariyani, Mochammad Arfin Fardiansyah Nasution, Arif Fadlan, Antonius Herry Cahyana, Erwahyuni Endang Prabandari, J. Carlos Menéndez

Research output: Contribution to journalArticlepeer-review


Eugenol, a primary component of clove oil, is a compound of considerable interest in medicinal chemistry due to its demonstrated potential as an effective agent in various therapeutic applications. In this study, a series of eugenol derivatives were designed and synthesized based on the hybridization of eugenol with 1,2,3-triazole and chalcone moieties. Compound 5j and 5k were denoted as lead structures against Mycobacterium tuberculosis Shikimate Kinase (MtSK). Moreover, the docking studies indicated that both the eugenol and triazole fragments in compound 5j and 5k played a pivotal role in the inhibition activity of MtSK, owing to their binding interactions with Arg58, Pro118, and Arg136 residues. Furthermore, in silico drug-likeness prediction analysis suggested that the majority of the synthesized compounds exhibit good oral bioavailability based on their molecular properties and Lipinski's Rule of Five predictions.

Original languageEnglish
Article number101826
JournalJournal of Saudi Chemical Society
Issue number2
Publication statusPublished - Mar 2024


  • 1,2,3-Triazole
  • Chalcone
  • Eugenol
  • M. tuberculosis
  • Shikimate Kinase


Dive into the research topics of 'Eugenol derivatives containing 1,2,3-triazole-chalcone hybrids for shikimate kinase inhibition'. Together they form a unique fingerprint.

Cite this